Precision Bio rises after Phase 1/2 data for gene editing therapy in OTC deficiency
Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...
bovnews1d
Breaking News: Why Precision BioSciences (DTIL) Is Dominating the Stock Market Today
Is it just market speculation, or is there something more significant unfolding behind the scenes? At the core of Precision BioSciences’ sudden stock surge is the company’s gene-editing technology, ...
Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst
Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...
Advancements in Precision BioSciences’ Gene Editing Platform Bolster Buy Rating
JonesTrading analyst Soumit Roy maintained a Buy rating on Precision BioSciences (DTIL – Research Report) today and set a price target of ...
Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly Buys 2,113 Shares
CFO John Alexander Kelly purchased 2,113 shares of Precision BioSciences stock in a transaction dated Friday, December 27th.
Precision BioSciences shares soar on promising gene editing trial results
Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a Phase 1/2 clinical trial. The ...
Pillar Biosciences Enters into Strategic Licensing Agreement for MSK's OncoKB™ Precision Medicine Knowledgebase
Pillar Biosciences, Inc. has entered into a strategic five-year licensing agreement with Memorial Sloan Kettering Cancer ...
TMCnet1d
Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine
Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...
PipelineReview.com5h
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC--First patient expected to be dosed in SURF302 in Q2 2025-CARLSBAD, CA, USA I J ...
Strong Buy Recommendation for Precision BioSciences: Promising Clinical Data and Favorable Valuation
BMO Capital analyst Kostas Biliouris upgraded the rating on Precision BioSciences (DTIL – Research Report) to a Buy today, setting a price ...